Tagged with EG

Mexico Pharmaceutical innovators are sounding the alarm on Mexico’s healthcare reforms, despite the government’s bold claims. At industry group AMIIF’s 75th anniversary, Health Secretary David Kershenobich hailed the Sheinbaum administration’s investments and regulatory shake‑up as game-changing. But pharma leaders argue that real-world access remains elusive, with one industry veteran warning it…

Brazil Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect of the organisation’s strategic transformation. His tenure spans critical periods of regulatory modernisation, digital transformation, and international collaboration, positioning him…

France Thomas Courbe, Director General for Enterprise at the French Ministry of Economy and Finance, has led France’s industrial transformation since 2019. He oversees, within the EURO 54 billion France 2030 plan, reforms in manufacturing, decarbonisation, and digital innovation. Under his leadership, France has become a top destination for foreign investment,…

Africa Writing in the July 2025 edition of DIA’s Global Forum magazine, Alex Juma Ismail of the African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) and Vicki Gold, a consultant to the Gates Foundation, unveil the “Continental List of Human Medicinal Products” pilot—a first-of-its-kind initiative led by the…

Switzerland Doetsch Grether may be 126 years old, but it is anything but traditional. With a portfolio that spans pharmaceuticals, consumer health, and retail – an uncommon mix for a company of its size – the Swiss firm is doubling down on focused expansion, values-driven culture, and long-term partnerships. For Wannhoff,…

Denmark While Big Pharma giants chase blockbuster drugs across multiple therapeutic areas, three Danish mid-cap companies are pursuing a different path to survival. Facing mounting pressures and global competition, ALK, LEO Pharma, and Lundbeck have turned to fresh leadership and bold transformation strategies. Drawing on exclusive interviews with the three CEOs…

France As global powers race to secure health sovereignty and industrial resilience, France stands at a crossroads. With rising regulatory asymmetries, fierce international competition, and mounting fiscal pressure on its pharmaceutical sector, the stakes have never been higher. Didier Véron, President of G5 Santé – the collective voice of France’s leading…

Switzerland Over the past decade, Dr Lutz Hegemann has helped transform Novartis’ Global Health unit into a strategic pillar that bridges innovation with real-world access. Rather than focusing on visibility, the mandate centres on sustainable impact; embedding access into R&D, rethinking the value of established medicines, and advocating for systemic change…

Denmark Neuroscience is once again at the forefront of medical innovation, and Lundbeck is seizing the moment to redefine its future. In this wide-ranging conversation, President & CEO Charl van Zyl outlines how the company is evolving from a heritage-rich organisation into a focused, performance-driven innovator with a maturing pipeline and…

Denmark Helene Probst, Health Director, Danish Regions, outlines Denmark’s healthcare reform as a major shift from hospital-centric care to a primary care-focused system, driven by workforce shortages and an ageing population. Key changes include redistributing responsibilities to regions, creating health councils, and redefining the GP role to better serve local and…

Denmark From its origins as the inventor of the world’s first self-inflating resuscitator bag in 1956 to becoming a global leader in single-use endoscopy, Ambu has always been defined by innovation. Today, under the leadership of CEO Britt Meelby Jensen, the company is undergoing a strategic transformation; centred on sharper focus,…

Europe As China and the US attract an increasing share of commercial clinical trials, Europe is fighting to reclaim its spot as a global research leader. While Europe has world-class hospitals and experienced regulators, it has struggled with a complicated and fragmented approval system that has pushed trial sponsors elsewhere. To…